Oncobax EH
Alternative Names: Oncobax®-EH; Oncobax®-EH - EverImmuneLatest Information Update: 05 Jul 2023
At a glance
- Originator EverImmune
- Class Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Breast cancer; Lung cancer
Most Recent Events
- 05 Jul 2023 Oncobax EH is available for licensing as of 04 Jul 2023. https://www.everimmune.net/partners (EverImmune website, July 2023)
- 04 Jul 2023 Clinical trials in Breast cancer (Adjuvant therapy) in France (PO), prior to July 2023 (EverImmune pipeline, July 2023)
- 04 Jul 2023 Clinical trials in Lung cancer (Adjuvant therapy) in France (PO), prior to July 2023 (EverImmune pipeline, July 2023)